TWI372147B - Quinazoline derivatives having a tyrosine kinase inhibitory activity - Google Patents

Quinazoline derivatives having a tyrosine kinase inhibitory activity

Info

Publication number
TWI372147B
TWI372147B TW095106013A TW95106013A TWI372147B TW I372147 B TWI372147 B TW I372147B TW 095106013 A TW095106013 A TW 095106013A TW 95106013 A TW95106013 A TW 95106013A TW I372147 B TWI372147 B TW I372147B
Authority
TW
Taiwan
Prior art keywords
tyrosine kinase
inhibitory activity
kinase inhibitory
quinazoline derivatives
quinazoline
Prior art date
Application number
TW095106013A
Other languages
English (en)
Other versions
TW200640880A (en
Inventor
Masaharu Kume
Kenji Matsuo
Naoki Omori
Masami Takayama
Aiko Omori
Takeshi Endo
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of TW200640880A publication Critical patent/TW200640880A/zh
Application granted granted Critical
Publication of TWI372147B publication Critical patent/TWI372147B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095106013A 2005-02-23 2006-02-23 Quinazoline derivatives having a tyrosine kinase inhibitory activity TWI372147B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005047383 2005-02-23
JP2005156828 2005-05-30

Publications (2)

Publication Number Publication Date
TW200640880A TW200640880A (en) 2006-12-01
TWI372147B true TWI372147B (en) 2012-09-11

Family

ID=36927355

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095106013A TWI372147B (en) 2005-02-23 2006-02-23 Quinazoline derivatives having a tyrosine kinase inhibitory activity

Country Status (16)

Country Link
US (2) US8202879B2 (zh)
EP (1) EP1854789B1 (zh)
JP (1) JP4137174B2 (zh)
KR (1) KR100910333B1 (zh)
CN (1) CN101163684B (zh)
AU (1) AU2006216266C1 (zh)
BR (1) BRPI0606905B1 (zh)
CA (1) CA2599328C (zh)
DK (1) DK1854789T3 (zh)
ES (1) ES2431843T3 (zh)
NO (1) NO343403B1 (zh)
PL (1) PL1854789T3 (zh)
PT (1) PT1854789E (zh)
RU (1) RU2414457C2 (zh)
TW (1) TWI372147B (zh)
WO (1) WO2006090717A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006090717A1 (ja) * 2005-02-23 2006-08-31 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するキナゾリン誘導体
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033749A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Quinazoline based egfr inhibitors containing a zinc binding moiety
EP2365962B1 (en) 2008-11-07 2017-07-05 Massachusetts Institute of Technology Aminoalcohol lipidoids and uses thereof
TWI466872B (zh) * 2008-12-25 2015-01-01 Shionogi & Co 喹唑啉衍生物之製造方法
KR102451116B1 (ko) * 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
CN103288756B (zh) * 2012-02-29 2016-04-20 江苏先声药物研究有限公司 一种喹唑啉中间体的甲醇溶剂合物及其制备方法
CN105407894A (zh) 2013-03-14 2016-03-16 康威基内有限公司 用于抑制含布罗莫结构域的蛋白质的方法和组合物
JP6099182B2 (ja) * 2014-05-29 2017-03-22 塩野義製薬株式会社 アルキニルケトン誘導体の製造方法
JP6334065B2 (ja) * 2015-07-29 2018-05-30 塩野義製薬株式会社 キナゾリン誘導体の塩またはその結晶およびそれらの製造方法
CA3000988A1 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN115806550A (zh) * 2015-11-25 2023-03-17 康威基内有限公司 双环bet布罗莫结构域抑制剂及其用途
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
JP7191446B2 (ja) * 2017-01-30 2022-12-19 塩野義製薬株式会社 キナゾリン誘導体を含有する固形製剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP3103799B1 (en) * 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
HUP0204413A3 (en) 1999-09-21 2003-07-28 Astrazeneca Ab Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them
CN1264824C (zh) 2001-02-21 2006-07-19 三菱制药株式会社 喹唑啉衍生物
WO2003031406A2 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
CA2497971A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
WO2004069145A2 (en) 2003-02-07 2004-08-19 Dr. Reddy's Laboratories Ltd. Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
WO2005067667A2 (en) 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2006090717A1 (ja) * 2005-02-23 2006-08-31 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するキナゾリン誘導体

Also Published As

Publication number Publication date
NO20074311L (no) 2007-11-23
EP1854789A4 (en) 2009-06-17
US20090143414A1 (en) 2009-06-04
AU2006216266C1 (en) 2010-08-26
BRPI0606905A2 (pt) 2009-07-28
CA2599328C (en) 2012-04-17
RU2007135023A (ru) 2009-03-27
AU2006216266B2 (en) 2010-02-18
AU2006216266A2 (en) 2006-08-31
CA2599328A1 (en) 2006-08-31
EP1854789A1 (en) 2007-11-14
TW200640880A (en) 2006-12-01
EP1854789B1 (en) 2013-10-09
CN101163684A (zh) 2008-04-16
JP4137174B2 (ja) 2008-08-20
ES2431843T3 (es) 2013-11-28
CN101163684B (zh) 2012-08-29
DK1854789T3 (da) 2013-10-21
KR20070098941A (ko) 2007-10-05
US8349857B2 (en) 2013-01-08
AU2006216266A8 (en) 2009-04-02
PL1854789T3 (pl) 2014-03-31
US8202879B2 (en) 2012-06-19
US20120123114A1 (en) 2012-05-17
JPWO2006090717A1 (ja) 2008-07-24
NO343403B1 (no) 2019-02-25
PT1854789E (pt) 2013-10-23
RU2414457C2 (ru) 2011-03-20
KR100910333B1 (ko) 2009-07-31
BRPI0606905B1 (pt) 2021-06-01
AU2006216266A1 (en) 2006-08-31
WO2006090717A1 (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
TWI372147B (en) Quinazoline derivatives having a tyrosine kinase inhibitory activity
AP3433A (en) Triazolopyridazines as tyrosine kinase modultors
HK1107339A1 (en) Quinazoline derivatives
HK1095590A1 (en) Quinazoline derivatives
IL191889A0 (en) Bicyclic compounds with kinase inhibitory activity
IL174261A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
EP1968950A4 (en) PYRIMIDINKINASEINHIBITOREN
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EG25942A (en) Quinazolinedione derivatives as parp inhibitors
EP1978958A4 (en) INHIBITION OF TYROSINE KINASE RET
ZA200610772B (en) Quinazolinone derivatives as PARP inhibitors
GB0403635D0 (en) Pyridinocarboxamides with improved activity as kinase inhibitors
IL190078A0 (en) Kinase inhibitors
ZA201005210B (en) Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
PL1943243T3 (pl) Inhibitory kinazy
IL196337A0 (en) Tyrosine kinase inhibitors
SI1896422T1 (sl) Tirosin kinazni inhibitorji
EP1773788B8 (en) Quinazoline derivatives
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
EP1951252A4 (en) INHIBITORS OF TYROSINE KINASES
EG24957A (en) Quinazoline derivatives as src tyrosine kinase inhibitors.
GB0504018D0 (en) Quinazoline derivatives
GB0405985D0 (en) Kinase
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EP1978964A4 (en) JAK2 tyrosine kinase Inhibition